Mustang Bio Licenses Gene Therapy from St. Jude Children Hospital to treat X-SCID (bubble boy) in newborns

 Mustang Bio Licenses Gene Therapy from St. Jude Children Hospital to treat X-SCID (bubble boy) in newborns

Mustang Bio Licenses Gene Therapy from St. Jude Children Hospital to treat X-SCID (bubble boy) in newborns

Shots:
  • St. Jude Children’s Research Hospital out-licenses exclusive worldwide rights for Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency also known as “bubble boy”
  • This therapy is presently being assessed in a phase I/II multicenter study in infants (Age ≥2)
  •  In Interim Analysis, 6/8 patients achieved reconstituted immune system within 3-4 mos of treatment, in addition to tolerability

Click here to read full press release/ article | Ref: Mustang Bio | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post